News

Beta-blockers and ED: A New Look After Heart Attack

A new analysis from the BETAMI-DANBLOCK trials reports a small, temporary increase in ED among men assigned beta-blockers after a heart attack, without a sustained difference in overall erectile-function scores. The finding complicates the assumption that a heart medicine necessarily explains every ongoing sexual problem after an infarction.

What the Sexual-function Analysis Found

The European Heart Journal published the conference abstract on October 26, 2026. The underlying trials randomized 5,574 patients after myocardial infarction who had a left ventricular ejection fraction of at least 40%. Among patients who reported recent sexual activity, 2,332 completed a sexual-function questionnaire at least once.

The investigators found no statistically significant effect of beta-blockers on the total erectile-function score over follow-up. They did find higher odds of ED at three months, but not at later time points. The abstract describes a transient signal, rather than evidence that every patient will have no sexual adverse effects or that the medicine cannot affect an individual.

This Result Applies to a Selected Heart-attack Population

The main BETAMI-DANBLOCK report concerns patients without heart failure and with preserved or mildly reduced pumping function. It compares a beta-blocker strategy with no beta-blocker strategy in that setting. The original trial asked about cardiovascular outcomes; the sexual-function analysis examines a more specific concern within its participants.

A reader should not extend that result to every reason for prescribing a beta-blocker. Someone with another indication, different heart function, or a different clinical history may face a different decision. The treating cardiologist needs to weigh the reason for the prescription alongside symptoms, rather than use a sexual-function abstract as a reason to stop treatment.

Recognizing a Possible Medicine Effect

NHS information lists erection difficulties among possible beta-blocker adverse effects and stresses that not everyone experiences them. It also advises patients not to stop a beta-blocker suddenly without medical advice. A review can consider the timing of symptoms, the medicine, its dose, and the condition that prompted treatment.

A useful symptom history distinguishes the weeks before the heart attack, the recovery period, and the time after starting or changing medicines. Tell the clinician about fatigue, low mood, anxiety about sex, and changes in exercise tolerance too. Those details help avoid attributing the whole problem to the most recently prescribed tablet.

Returning to Sex Requires a Heart-health Conversation

The American Heart Association encourages people with cardiovascular disease to discuss sexual activity with their healthcare team. Cardiac rehabilitation and physical activity can support recovery, and a clinician can advise whether the condition is stable enough for sexual activity. Fear of another event can itself affect how a person approaches intimacy.

The association also warns against combining nitrate treatment for chest pain with ED medicines. That interaction needs a review before a prescription, regardless of whether the patient thinks a beta-blocker caused his erection problem. Bring the complete medicine list, including medicines used only occasionally, rather than name only the daily tablets.

What the Abstract Leaves Open

A questionnaire provides information about the participants who complete it. Men who do not report recent sexual activity or do not return questionnaires may have different experiences. The abstract cannot describe every reason for nonresponse or answer all questions about individual medicines and doses.

The difference between an average score and the odds of crossing an ED threshold also deserves attention. A small change can affect how some men fall into a category without producing a large group difference on the full scale. The report needs interpretation in context, including the time point and the outcome the researchers measured.

Timing Can Help Interpret the Pattern

The investigators assessed participants at several follow-up points, so the early signal and the later results describe different stages of recovery. An effect at three months does not establish that the same pattern continues indefinitely, while a later group average does not erase an individual's earlier difficulty.

That is why a timeline belongs in a medication review. Note whether symptoms began immediately, improved during recovery, or persisted after other aspects of health stabilized. Ask the clinician what the pattern suggests and what would justify another assessment. Do not use a change in symptoms as a reason to stop a heart medicine without advice.

How to Raise the Concern Without Interrupting Treatment

Tell your cardiologist or prescribing clinician that sexual function has changed and ask for a medication review. Ask which prescriptions remain necessary, whether alternatives make sense, and whether a separate ED assessment would help. Do not skip doses as an informal test of the theory.

Our ED assessment guide explains the history to bring. The treatment overview covers options to discuss after the clinician has reviewed cardiovascular status and potential interactions.

Sources

Comments

Leave a comment